---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025506"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-08-04T11:00:10+00:00"
generated_at: "2026-08-04T11:05:04.866431+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals appoints Danka Radosavljevic as COO

## Summary
- Danka Radosavljevic appointed COO effective July 31, 2026; previously EVP of Operations since 2017.
- Annual base salary set at $520,800; discretionary bonus target of 50% of base salary.
- Radosavljevic oversaw quality, product development, regulatory, supply chain, and IT in prior role.

## SEC filing metadata
- accession: 0001437749-26-025506
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-08-04T11:00:10+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926025506/0001437749-26-025506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926025506/eton20260731_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025506
- JSON: https://secwatch.observer/filing/0001437749-26-025506.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.